|
TOP
|
|
VIEKIRA XR(dasabuvir, ombitasvir, paritaprevir, and ritonavir)extended-release tablets(十三)
cal monitoring of patients is recommended and therapy should be individualized based on patient’s response.
ANTIRETROVIRAL AGENTS: PROTEASE INHIBITORS
atazanavir/ritonavir
once daily ↑ paritaprevir When coadministered with VIEKIRA XR, atazanavir 300 mg (without ritonavir) should only be given in the morning.
darunavir/ritonavir ↓ darunavir (Ctrough) Treatment naïve patients or treatment experienced patients with no darunavir associated substitutions:
Darunavir 800 mg once daily (without ritonavir) can be co-administered with VIEKIRA XR.
Treatment experienced patients with at least one darunavir resistance associated substitution or with no baseline resistance information:
Co-administration of darunavir/ritonavir 600/100 mg twice daily with VIEKIRA XR is not recommended.
lopinavir/ritonavir ↑ paritaprevir Co-administration of VIEKIRA XR with lopinavir/ritonavir is not recommended.
ANTIRETROVIRAL AGENTS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
rilpivirine ↑ rilpivirine Contraindicated non-nucleoside reverse transcriptase inhibitors [see Contraindications (4)].
Rilpivirine:
Co-administration of VIEKIRA XR with rilpivirine once daily is not recommended due to potential for QT interval prolongation with higher concentrations of rilpivirine.
HMG CoA REDUCTASE INHIBITORS:
pravastatin
rosuvastatin ↑ pravastatin
↑ rosuvastatin Contraindicated HMG CoA Reductase Inhibitors [see Contraindications (4)].
Rosuvastatin:
Dose of rosuvastatin should not exceed 10 mg per day.
Pravastatin:
Dose of pravastatin should not exceed 40 mg per day.
IMMUNOSUPPRESSANTS
cyclosporine ↑ cyclosporine For contraindicated immunosuppressants [see Contraindications (4)].
When initiating therapy with VIEKIRA XR, reduce cyclosporine dose to 1/5th of the patient’s current cyclosporine dose. Measure cyclosporine blood concentrations to determine subsequent dose modifications. Upon completion of VIEKIRA XR therapy, the appropriate time to resume pre-VIEKIRA XR dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations. Frequent assessment of renal function and cyclosporine-related side effects is recommended.
LONG ACTING BETA-ADRENOCEPTOR AGONIST
salmeterol* ↑ salmeterol Concurrent administration of VIEKIRA XR and salmeterol is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
MUSCLE RELAXANTS
carisoprodol ↓ carisoprodol
↔ mepobramate
(metabolite of
carisoprodol) Increase dose if clinically indicated.
cyclobenzaprine ↓cyclobenzaprine
↓norcyclobenzaprine
(metabolite of
cyclobenzaprine) Increase dose if clinically indicated.
NARCOTIC ANALGESICS
acetaminophen/hydrocodone ↑ hydrocodone
↔ acetaminophen Reduce the dose of hydrocodone by 50% and monitor patients for respiratory depression and sedation at frequent intervals. Upon completion of VIEKIRA XR therapy, adjust the hydrocodone dose and monitor for signs of opioid withdrawal.
buprenorphine/naloxone ↑ bupren |
|
